Journal
Clinical Lymphoma Myeloma and Leukemia
Publication Date
3-1-2022
Volume
22
Issue
3
First Page
158
Last Page
168
Document Type
Open Access Publication
DOI
10.1016/j.clml.2021.09.001
Rights and Permissions
Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-168. doi: 10.1016/j.clml.2021.09.001. © 2021 ADC Therapeutics. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Recommended Citation
Spira, Alexander; Zhou, Xiaolei; Chen, Lei; Gnanasakthy, Ari; Wang, Luqiang; Ungar, David; Curiel, Rafael; Liao, Laura; Radford, John; and Kahl, Brad, "Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma." Clinical Lymphoma Myeloma and Leukemia. 22, 3. 158 - 168. (2022).
https://digitalcommons.wustl.edu/oa_4/1783
Additional Links
Supplemental material is available for this article at publisher site.
